N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery | Zendy

Stephanie Pollock | Zendy; Raymond A. Dwek | Zendy; Dennis R. Burton | Zendy; Nicole Zitzmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery

Author(s) -

Stephanie Pollock,

Raymond A. Dwek,

Dennis R. Burton,

Nicole Zitzmann

Publication year - 2008

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e32830efd96

Subject(s) - liposome , infectivity , peripheral blood mononuclear cell , virology , pharmacology , viral load , ic50 , drug delivery , drug , medicine , virus , immunology , biology , in vitro , chemistry , biochemistry , organic chemistry

N-Butyldeoxynojirimycin (NB-DNJ), an inhibitor of HIV gp120 folding, was assessed as a broadly active therapy for the treatment of HIV/AIDS. Furthermore, to reduce the effective dose necessary for antiviral activity, NB-DNJ was encapsulated inside liposomes and targeted to HIV-infected cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research